Clinical trials: Recurrent Ovarian Carcinoma
Ovarian Cancer, Fallopian Tube Cancer
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
This trial is a Phase Ib/II study of carboplatin/gemcitabine/vorinostat for the treatment of platinum sensitive recurrent ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00910000
- Testing
- Vorinostat, Carboplatin, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer Recurrent, Ovarian Cancer
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101.
- Conditions
- Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
- Trial name
- NCT07030907
- Testing
- OPB-101
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Outpace Bio, Inc.
Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer).
- Conditions
- Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer, Relapsed Fallopian Tube Cancer
- Trial name
- NCT01940172
- Testing
- Birinapant, Conatumumab
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- TetraLogic Pharmaceuticals
Ovarian Cancer, Ovary Neoplasm
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
A phase III prospective study with the primary objective to compare the efficacy and safety of HIPEC( Hyperthermic Intraperitoneal Chemotherapy).
- Conditions
- Ovarian Cancer, Ovary Neoplasm, Ovarian Neoplasms, Epithelial Ovarian Cancer
- Trial name
- HIPECOV (NCT03371693)
- Testing
- HIPEC, CRS, IVCT
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Zhongnan Hospital
Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Akt inhibitor MK2206 is a drug that may stop cancer cells from growing by blocking a protein called protein kinase B (AKT) inside the cell.
- Conditions
- Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01283035
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
Of the approximately 21,000 cases of ovarian cancer diagnosed annually in the U.S, ten percent are attributed to hereditary syndromes, most commonly the result of mutations in the breast cancer susceptibility genes 1 or 2 (BRCA1…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT02571725
- Testing
- Olaparib, Tremelimumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- New Mexico Cancer Research Alliance
Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel…
- Conditions
- Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer
- Trial name
- STAPOVER (NCT03458221)
- Testing
- Letrozole Oral Product, Bicalutamide Oral Product, Everolimus Oral Product
- Where
- 6 sites in Netherlands
- Volunteers
- 148 people
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
Recurrent Ovarian Cancer
Combination Therapy for Recurrent Ovarian Cancer
The proposed study "combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in recurrent ovarian cancer" is focused to determine the feasibility and maximum tolerance dose of Ashwagandha with liposomal…
- Trial name
- NCT05610735
- Testing
- DOXIL, Withaferin A, Ashwagandha
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Sham Sunder Kakar
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002508
- Testing
- carboplatin, etoposide, autologous bone marrow transplantation
- Where
- United States
- Sponsor
- Temple University
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT06483048
- Testing
- Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Ovarian Squamous Cell Carcinoma
Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
This is a phase II, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of MK-3475 in patients with ovarian squamous cell carcinoma.
- Trial name
- NCT05737199
- Testing
- MK-3475 (pembrolizumab)
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Niigata University Medical & Dental Hospital
Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00003413
- Testing
- filgrastim, carmustine, cisplatin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Maryland, Baltimore
Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
This phase I trial studies the side effects and best dose of activated T-cell therapy when given together with low-dose aldesleukin and sargramostim in treating patients with ovarian, fallopian tube, or primary peritoneal cancer…
- Conditions
- Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02470559
- Testing
- Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Fallopian Tube Cancer, Ovarian Cancer
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Progesterone can cause the growth of ovarian epithelial cancer , primary peritoneal cancer, or fallopian tube cancer.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00459290
- Testing
- mifepristone
- Where
- 22 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Study of Ramucirumab in Ovarian Cancer
The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT00721162
- Testing
- Ramucirumab
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer Recurrent
Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer
This is a feasibility single-center study to investigate the tolerability, toxicity, quality of life, morbidity, mortality of the HIPEC treatment following cytoreductive surgery for treatment of recurrent ovarian, peritoneal, and…
- Trial name
- NCT03717610
- Testing
- radical surgery with HIPEC
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Uppsala University Hospital
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04498520
- Testing
- Abexinostat Tosylate, Fulvestrant, Palbociclib
- Sponsor
- Pamela Munster
Relapsed Ovarian Cancer
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
This study is a Phase II randomized, open label, controlled, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy for maintenance treatment in…
- Trial name
- NCT05479487
- Testing
- Fluzoparib+Apatinib, Fluzoparib Monotherapy
- Volunteers
- 132 people
- Sponsor
- Xiaohua Wu MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.